

A Simple Synthetic Route to Statine and Statine Analogues

M. T. Reetz,* M. W. Drewes, B. R. Matthews, and K. Lennick

Fachbereich Chemie der Universität, Hans-Meerwein-Strasse, 3550 Marburg, Federal Republic of Germany


The biologically important amino acid statine, (3*S*,4*S*)-4-amino-3-hydroxy-6-methylheptanoic acid, as well as optically active statine analogues, are readily accessible in the ester form by simple reduction of the corresponding *N,N*-dibenzyl β -keto esters using NaBH₄ followed by deprotection.

Chiral β -amino alcohols are biologically and pharmacologically interesting compounds.¹ An example is statine (**1**), a constituent of the naturally occurring small peptide pepstatin which is a strong inhibitor of such aspartic proteinases as pepsin, renin, and cathepsin.² Since renin inhibitors are currently of great interest in the treatment of hypertension and congestive heart failure, considerable efforts have gone into the synthesis of statine and statine analogues.³

Since the (3*S*,4*S*)-configuration is an essential requirement for biological activity, stereoselective routes are required. The most efficient approach to date involves the conversion of *t*-butoxycarbonyl (Boc) protected L-amino acids into the corresponding β -keto esters (**2**) followed by reduction to (**3**). Unfortunately, common achiral reducing agents such as NaBH₄ or NaCNBH₃ lead to mixtures of diastereoisomers (**3**)/(**4**) or to the wrong (3*R*,4*S*)-diastereoisomer (**4**), and bulky reagents such as K(Bu^s)₃BH afford <25% of (**3**).^{3–5} Therefore, *chiral* reducing agents had to be applied, *e.g.*, enzymes⁵ or optically active Wilkinson catalysts.⁶

We now report an unusually simple synthesis of (**1**) and analogues which *relies solely on the influence of the chiral centre already present in the precursor* (Scheme 1).

Naturally occurring L-amino acids (**5**) were first protected at nitrogen to provide the *N,N*-dibenzylated acid derivatives (**6**), which were then converted into the imidazolides. Without isolation the latter were allowed to react with the magnesium enolate of malonic acid monoethyl ester⁷ at 0 \rightarrow 40 °C, affording after acidic work-up the keto esters (**7**). These are also accessible by the reaction of the lithium enolate of ethyl acetate with the imidazolides at –78 °C (70–78% yield) or with the benzyl esters⁹ of (**6**) (40%). The decisive reduction of (**7**) using NaBH₄ in methanol at –20 °C occurred stereoselectively with non-chelation control⁸ to form the desired (*S,S*)-products (**8**) preferentially (Scheme 1). Non-chelation control is also observed in Grignard and aldol additions to the analogous *N,N*-dibenzylamino aldehydes and is in line with the Felkin–Anh model.⁹ Control experiments show that compounds (**9**) are enantiomerically pure [enantiomeric



excess (e.e.) 99% for (9a) and (9b); 97% for (9c)],¹⁰ proving that essentially no racemization occurs at any stage of the sequence. This was accomplished by acylating the pure diastereoisomers (8) using (*R*)(+)-2-methoxy- α -trifluoromethylphenylacetyl chloride¹⁰ and investigating the products by ¹³C and ¹⁹F n.m.r. spectroscopy as well as h.p.l.c. Essentially only one diastereoisomer was detected, in contrast to the results obtained when working in the racemic series using (\pm)-amino acids as starting materials. The products are readily deprotected using Pd-black/HCO₂H/MeOH;⁹ e.g. (9a) gives the corresponding free amine in 85% yield.


Since the above four-step sequence can be performed on a multigram scale, it constitutes a simple synthesis of statine-like compounds using cheap reagents and reaction partners. It can also be used to prepare the (*R,R*)-enantiomers starting from D-amino acids. The present method is stereochemically complementary to the previously described non-chelation-controlled aldol additions of lithium enolates to *N,N*-dibenzyl α -amino aldehydes which provide 95% of the (*S,R*)- or (*R,S*)-diastereoisomers.⁹ Both methods demonstrate the power of 'protective group tuning,' Boc and 9-phenylfluoren-9-yl protective groups generally leading to mixtures of diastereoisomers.^{1,3-5,7,11}

This work was supported by the Deutsche Forschungsgemeinschaft (SFB 260) and the Fonds der Chemischen Industrie.

Received, 25th April 1989; Com. 9/01741K

References

- 1 J. Jurczak and A. Golebiowski, *Chem. Rev.*, 1989, **89**, 149.
- 2 U. Umezawa, T. Aoyagi, H. Morishima, M. Matzusaki, H. Hamada, and T. Takeuchi, *J. Antibiot.*, 1970, **23**, 259; D. H. Rich, *J. Med. Chem.*, 1985, **28**, 264.
- 3 See for example: K. E. Rittle, C. F. Homnick, G. S. Ponticello, and B. E. Evans, *J. Org. Chem.*, 1982, **47**, 3016; M. W. Hollaway, F. G. Salituro, and D. H. Rich, *J. Med. Chem.*, 1987, **30**, 374; P. W. K. Woo, *Tetrahedron Lett.*, 1985, **26**, 2973; S. Danishefsky,



Scheme 1. Reagents and conditions: i, K₂CO₃/BnBr (Bn = PhCH₂),⁹ then KOH/H₂O/dioxane; ii, *N,N*-carbonyldi-imidazole, then PrⁱMgCl/CH₂(CO₂Et)CO₂H;⁷ iii, NaBH₄/MeOH, -20 °C.

- S. Kobayashi, and J. F. Kerwin, Jr., *J. Org. Chem.*, 1982, **47**, 1981;
- M. N. Dufour, P. Jouin, J. Poncet, A. Pantaloui, and B. Castro, *J. Chem. Soc., Perkin Trans. 1*, 1986, 1895; K. Kogen and T. Nishi, *J. Chem. Soc., Chem. Commun.*, 1987, 311; H. J. Schostarez, *J. Org. Chem.*, 1988, **53**, 3628; see also ref. 6 and references cited therein.
- 4 J. Maibaum and D. H. Rich, *J. Org. Chem.*, 1988, **53**, 869; P. F. Schuda, W. J. Greenlee, P. K. Chakravarty, and P. Eskola, *J. Org. Chem.*, 1988, **53**, 873; B. D. Harris and M. M. Joullie, *Tetrahedron*, 1988, **44**, 3489; Y. Hamada, Y. Kondo, M. Shibata, and T. Shioiri, *J. Am. Chem. Soc.*, 1989, **111**, 669.
- 5 P. Raddatz, H. E. Radunz, G. Schneider, and H. Schwartz, *Angew. Chem.*, 1988, **100**, 414; *Angew. Chem., Int. Ed. Engl.*, 1988, **27**, 426.
- 6 T. Nishi, M. Kitamura, T. Ohkuma, and R. Noyori, *Tetrahedron Lett.*, 1988, **29**, 6327.
- 7 R. Steulmann and H. Klostermeyer, *Liebigs Ann. Chem.*, 1975, 2245.
- 8 Chelation or non-chelation controlled addition reactions of chiral alkoxy carbonyl compounds: M. T. Reetz, *Angew. Chem.*, 1984, **96**, 542; *Angew. Chem., Int. Ed. Engl.*, 1984, **23**, 556.
- 9 M. T. Reetz, M. W. Drewes, and A. Schmitz, *Angew. Chem.*, 1987, **99**, 1186; *Angew. Chem., Int. Ed. Engl.*, 1987, **26**, 1141.
- 10 J. A. Dale, D. L. Dull, and H. S. Mosher, *J. Org. Chem.*, 1969, **34**, 2543.
- 11 W. D. Lubell and H. Rapoport, *J. Am. Chem. Soc.*, 1988, **110**, 7447.